혈역학적 모니터링 기기 시장 규모, 점유율 및 동향 분석 보고서 : 시스템 유형별, 제품별, 최종 용도별, 지역별, 부문 예측(2025-2033년)

Hemodynamic Monitoring Devices Market Summary

The global hemodynamic monitoring devices market size was estimated at USD 1.58 billion in 2024 and is projected to reach USD 2.78 billion by 2033, growing at a CAGR of 6.5% from 2025 to 2033. The growth is driven by several key factors, such as the rising prevalence of cardiovascular diseases and critical illnesses, integration of AI and predictive analytics, growing demand for minimally invasive and non-invasive monitoring techniques, and technological advancements in monitoring devices, including real-time data and wireless connectivity.

The increasing prevalence of CVDs and associated risk factors is anticipated to boost the demand for hemodynamic monitoring devices. Hemodynamic monitoring devices play an increasingly important role in assessing and reducing the risk of heart failure. Hemodynamic monitoring devices, such as implantable devices, provide objective data on factors like pulmonary artery pressure. This allows doctors to identify patients at higher risk for hospitalization or even death from heart failure. Heart failure is one of the leading causes of death across the globe; for instance, according to the CDC, around 6.7 million adults of 20 years and older in the U.S. have heart failure.

In addition, the demand in the hemodynamic monitoring devices industry is constantly growing due to the rising prevalence of Sudden Cardiac Arrests (SCA). Cardiac arrests are generally severe or fatal, and the survival rate in several countries is low, mainly in cases of out-of-hospital attacks. According to the Heart and Stroke Statistics 2022 by the American Heart Association, more than 356,000 out-of-hospital cardiac arrests occur in the U.S. every year, with around 90% of them resulting in death. Hence, the increasing prevalence of cardiac arrest is anticipated to boost the demand for pacemakers.

The aging process significantly changes the cardiovascular system, making careful hemodynamic management essential for older ICU patients. As people age, the balance of the autonomic nervous system gradually shifts: parasympathetic activity weakens while resting sympathetic activity increases. This imbalance heightens the risk of cardiovascular complications in elderly individuals.

At the same time, the global population is aging rapidly. According to the WHO, the number of people aged 60 and above is projected to rise from around 1 billion in 2020 to 1.4 billion by 2030, reaching approximately 2.1 billion by 2050. Consequently, the number of elderly patients experiencing critical illnesses has grown substantially in recent years, underscoring the increasing need for advanced hemodynamic monitoring in this vulnerable population.

Global Hemodynamic Monitoring Devices Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global hemodynamic monitoring devices market report based on system type, product, end use, and region:

• System Type Outlook (Revenue, USD Million, 2021 - 2033)
• Invasive
• Minimally Invasive
• Non-Invasive
• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Disposables
• Monitors
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals
• Catheterization Labs
• Other
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Sweden
  • Denmark
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. System Type
  • 1.2.2. Product
  • 1.2.3. End Use
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Rising prevalence of cardiovascular diseases and critical illnesses.
    • 3.2.1.2. Growing demand for minimally invasive and non-invasive monitoring techniques.
    • 3.2.1.3. Technological advancements in monitoring devices, including real-time data and wireless connectivity.
    • 3.2.1.4. Adoption of remote patient monitoring and tele-ICU solutions.
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High cost of advanced hemodynamic monitoring systems
    • 3.2.2.2. Risk of complications with invasive monitoring methods
  • 3.2.3. Industry Opportunity Analysis
  • 3.2.4. Industry Challenge Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Porter's Five Forces Analysis
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTLE Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic and Social landscape
    • 3.3.2.3. Technological landscape
    • 3.3.2.4. Environmental landscape
    • 3.3.2.5. Legal Landscape

Chapter 4. Hemodynamic Monitoring Devices Market: System Type Estimates & Trend Analysis

• 4.1. System Type Segment Dashboard
• 4.2. System Type Market Share Movement Analysis, 2024 & 2033
• 4.3. Market Size & Forecasts and Trend Analysis, by System Type, 2021 to 2033 (USD Million)
• 4.4. Invasive
  • 4.4.1. Market estimates and forecast 2021 to 2033, (USD Million)
• 4.5. Minimally Invasive
  • 4.5.1. Market estimates and forecast 2021 to 2033, (USD Million)
• 4.6. Non-Invasive
  • 4.6.1. Market estimates and forecast 2021 to 2033, (USD Million)

Chapter 5. Hemodynamic Monitoring Devices Market: Products Estimates & Trend Analysis

• 5.1. Products Segment Dashboard
• 5.2. Products Market Share Movement Analysis, 2024 & 2033
• 5.3. Market Size & Forecasts and Trend Analysis, by Products, 2021 to 2033 (USD Million)
• 5.4. Disposables
  • 5.4.1. Market estimates and forecast 2021 to 2033, (USD Million)
• 5.5. Monitors
  • 5.5.1. Market estimates and forecast 2021 to 2033, (USD Million)

Chapter 6. Hemodynamic Monitoring Devices Market: End Use Estimates & Trend Analysis

• 6.1. End Use Segment Dashboard
• 6.2. End Use Market Share Movement Analysis, 2024 & 2033
• 6.3. Market Size & Forecasts and Trend Analysis, by End Use, 2021 to 2033 (USD Million)
• 6.4. Hospitals
  • 6.4.1. Market estimates and forecast 2021 to 2033, (USD Million)
• 6.5. Catheterization Labs
  • 6.5.1. Market estimates and forecast 2021 to 2033, (USD Million)
• 6.6. Others
  • 6.6.1. Market estimates and forecast 2021 to 2033, (USD Million)

Chapter 7. Hemodynamic Monitoring Devices Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Dashboard
• 7.2. Regional Market: Key Takeaways
• 7.3. North America
  • 7.3.1. North America Hemodynamic monitoring devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.3.2. U.S.
  • 7.3.3. Key country dynamics
    • 7.3.3.1. Regulatory framework/Reimbursement Scenario
    • 7.3.3.2. Competitive insights
    • 7.3.3.3. U.S. Hemodynamic monitoring devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.3.4. Canada
    • 7.3.4.1. Key country dynamics
    • 7.3.4.2. Regulatory framework/Reimbursement Scenario
    • 7.3.4.3. Competitive insights
    • 7.3.4.4. Canada Hemodynamic monitoring devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.3.5. Mexico
    • 7.3.5.1. Key country dynamics
    • 7.3.5.2. Regulatory framework/Reimbursement Scenario
    • 7.3.5.3. Competitive insights
    • 7.3.5.4. Mexico Hemodynamic monitoring devices market estimates and forecasts, 2021 - 2033 (USD Million)
• 7.4. Europe
  • 7.4.1. Europe Hemodynamic monitoring devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.2. Germany
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Regulatory framework/Reimbursement Scenario
    • 7.4.2.3. Competitive insights
    • 7.4.2.4. Germany Hemodynamic monitoring devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.3. UK
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Regulatory framework/Reimbursement Scenario
    • 7.4.3.3. Competitive insights
    • 7.4.3.4. UK Hemodynamic monitoring devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.4. France
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Regulatory framework/Reimbursement Scenario
    • 7.4.4.3. Competitive insights
    • 7.4.4.4. France Hemodynamic monitoring devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.5. Italy
    • 7.4.5.1. Key country dynamics
    • 7.4.5.2. Regulatory framework/Reimbursement Scenario
    • 7.4.5.3. Competitive insights
    • 7.4.5.4. Italy Hemodynamic monitoring devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.6. Spain
    • 7.4.6.1. Key country dynamics
    • 7.4.6.2. Regulatory framework/Reimbursement Scenario
    • 7.4.6.3. Competitive insights
    • 7.4.6.4. Spain Hemodynamic monitoring devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.7. Denmark
    • 7.4.7.1. Key country dynamics
    • 7.4.7.2. Regulatory framework/Reimbursement Scenario
    • 7.4.7.3. Competitive insights
    • 7.4.7.4. Denmark Hemodynamic monitoring devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.8. Sweden
    • 7.4.8.1. Key country dynamics
    • 7.4.8.2. Regulatory framework/Reimbursement Scenario
    • 7.4.8.3. Competitive insights
    • 7.4.8.4. Sweden Hemodynamic monitoring devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.9. Norway
    • 7.4.9.1. Key country dynamics
    • 7.4.9.2. Regulatory framework/Reimbursement Scenario
    • 7.4.9.3. Competitive insights
    • 7.4.9.4. Norway Hemodynamic monitoring devices market estimates and forecasts, 2021 - 2033 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Asia Pacific Hemodynamic monitoring devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.5.2. Japan
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/Reimbursement Scenario
    • 7.5.2.3. Competitive insights
    • 7.5.2.4. Japan Hemodynamic monitoring devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.5.3. China
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/Reimbursement Scenario
    • 7.5.3.3. Competitive insights
    • 7.5.3.4. China Hemodynamic monitoring devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.5.4. India
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework/Reimbursement Scenario
    • 7.5.4.3. Competitive insights
    • 7.5.4.4. India Hemodynamic monitoring devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.5.5. South Korea
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Regulatory framework/Reimbursement Scenario
    • 7.5.5.3. Competitive insights
    • 7.5.5.4. South Korea Hemodynamic monitoring devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.5.6. Australia
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Regulatory framework/Reimbursement Scenario
    • 7.5.6.3. Competitive insights
    • 7.5.6.4. Australia Hemodynamic monitoring devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.5.7. Thailand
    • 7.5.7.1. Key country dynamics
    • 7.5.7.2. Regulatory framework/Reimbursement Scenario
    • 7.5.7.3. Competitive insights
    • 7.5.7.4. Thailand Hemodynamic monitoring devices market estimates and forecasts, 2021 - 2033 (USD Million)
• 7.6. Latin America
  • 7.6.1. Latin America Hemodynamic Monitoring Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.2. Brazil
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/Reimbursement Scenario
    • 7.6.2.3. Competitive insights
    • 7.6.2.4. Brazil Hemodynamic monitoring devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.6.3. Argentina
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Regulatory framework/Reimbursement Scenario
    • 7.6.3.3. Competitive insights
    • 7.6.3.4. Argentina Hemodynamic monitoring devices market estimates and forecasts, 2021 - 2033 (USD Million)
• 7.7. MEA
  • 7.7.1. MEA Hemodynamic monitoring devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.7.2. South Africa
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/Reimbursement Scenario
    • 7.7.2.3. Competitive insights
    • 7.7.2.4. South Africa Hemodynamic monitoring devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.7.3. Saudi Arabia
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/Reimbursement Scenario
    • 7.7.3.3. Competitive insights
    • 7.7.3.4. Saudi Arabia Hemodynamic monitoring devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.7.4. UAE
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/Reimbursement Scenario
    • 7.7.4.3. Competitive insights
    • 7.7.4.4. UAE Hemodynamic monitoring devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.7.5. Kuwait
    • 7.7.5.1. Key country dynamics
    • 7.7.5.2. Regulatory framework/Reimbursement Scenario
    • 7.7.5.3. Competitive insights
    • 7.7.5.4. Kuwait Hemodynamic monitoring devices market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Participant Overview
• 8.2. Company Market Share/Position Analysis, 2024 (%)
• 8.3. Company Categorization
• 8.4. Strategy Mapping
• 8.5. Company Profiles/Listing
  • 8.5.1. BD
    • 8.5.1.1. Overview
    • 8.5.1.2. Financial performance
    • 8.5.1.3. Product benchmarking
    • 8.5.1.4. Strategic initiatives
  • 8.5.2. GE HealthCare
    • 8.5.2.1. Overview
    • 8.5.2.2. Financial performance
    • 8.5.2.3. Product benchmarking
    • 8.5.2.4. Strategic initiatives
  • 8.5.3. Baxter
    • 8.5.3.1. Overview
    • 8.5.3.2. Financial performance
    • 8.5.3.3. Product benchmarking
    • 8.5.3.4. Strategic initiatives
  • 8.5.4. ICU Medical, Inc.
    • 8.5.4.1. Overview
    • 8.5.4.2. Financial performance
    • 8.5.4.3. Product benchmarking
    • 8.5.4.4. Strategic initiatives
  • 8.5.5. Koninklijke Philips N.V.
    • 8.5.5.1. Overview
    • 8.5.5.2. Financial performance
    • 8.5.5.3. Product benchmarking
    • 8.5.5.4. Strategic initiatives
  • 8.5.6. Masimo Corporation
    • 8.5.6.1. Overview
    • 8.5.6.2. Financial performance
    • 8.5.6.3. Product benchmarking
    • 8.5.6.4. Strategic initiatives
  • 8.5.7. Deltex Medical Limited
    • 8.5.7.1. Overview
    • 8.5.7.2. Financial performance
    • 8.5.7.3. Product benchmarking
    • 8.5.7.4. Strategic initiatives
  • 8.5.8. Getinge
    • 8.5.8.1. Overview
    • 8.5.8.2. Financial performance
    • 8.5.8.3. Product benchmarking
    • 8.5.8.4. Strategic initiatives
  • 8.5.9. Nihon Kohden Corporation
    • 8.5.9.1. Overview
    • 8.5.9.2. Financial performance
    • 8.5.9.3. Product benchmarking
    • 8.5.9.4. Strategic initiatives
  • 8.5.10. OSYPKA MEDICAL
    • 8.5.10.1. Overview
    • 8.5.10.2. Financial performance
    • 8.5.10.3. Product benchmarking
    • 8.5.10.4. Strategic initiatives
  • 8.5.11. Schwarzer Cardiotek GmbH
    • 8.5.11.1. Overview
    • 8.5.11.2. Financial performance
    • 8.5.11.3. Product benchmarking
    • 8.5.11.4. Strategic initiatives
  • 8.5.12. Caretaker Medical
    • 8.5.12.1. Overview
    • 8.5.12.2. Financial performance
    • 8.5.12.3. Product benchmarking
    • 8.5.12.4. Strategic initiatives
  • 8.5.13. Medtronic
    • 8.5.13.1. Overview
    • 8.5.13.2. Financial performance
    • 8.5.13.3. Product benchmarking
    • 8.5.13.4. Strategic initiatives
  • 8.5.14. Retia Medical Systems, Inc.
    • 8.5.14.1. Overview
    • 8.5.14.2. Financial performance
    • 8.5.14.3. Product benchmarking
    • 8.5.14.4. Strategic initiatives
  • 8.5.15. Sramek BioDynamics, Inc.
    • 8.5.15.1. Overview
    • 8.5.15.2. Financial performance
    • 8.5.15.3. Product benchmarking
    • 8.5.15.4. Strategic initiatives